Harrow (HROW) said Thursday that a California jury ruled in favor of its subsidiary ImprimisRx in a trademark infringement against OSRX and Ocular Science.
The jury awarded $34.9 million in damages, which included $20.4 million in punitive damages and $14.5 million is actual damages, Harrow said.
OSRX did not immediately respond to a request by MT Newswires for comment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。